Camilla Foged (CF) is heading the Vaccine Design and Delivery Group in the Section for Biologics, Department of Pharmacy, University of Copenhagen, Denmark, which comprises about 10 researchers. Our research interest is advanced drug delivery, and we design new vaccine and nucleic acid delivery systems to improve therapy. The group is addressing drug delivery challenges using state-of-the-art technologies, and this has fostered innovative solutions and high impact publications in drug delivery. Our research goal is to improve disease prevention and treatment in the fields of infectious and inflammatory diseases. We do this by imaging-guided design of nanoparticulate vaccine and nucleic acid formulations through an in depth knowledge of how the physicochemical properties of the particles affect their interaction with the environment, e.g. in formulation, in vitro and in vivo. We are one of the leading groups in the world in the area of quality-by-design based engineering of high-quality and robust nanomedicine formulations. We engage in research projects spanning from early discovery phase projects to first-in-man clinical studies. We address basic scientific questions in the field, and we are actively engaged in translational research. CF is widely recognized nationally and internationally in the field of drug delivery, and she has a well-established and extensive network of national and international collaborators in academia and industry. International collaboration partners include Yale University, MIT, Université Catholique de Louvain, University of Cambridge, University of Gröningen, Universitätsklinikum Erlangen, Ludwig-Maximilans Universität München, University of Paris-Sud, Utrecht University, GSK and Sanofi. She has a track record in conducting and leading interdisciplinary research in collaboration with large international consortia. Her research has been funded with more than EUR 7 million by the Danish Research Councils, Universities, private companies, private foundations and EU.